In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-15-2644PMID 27197149PMCID PMC4930687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

  2015cited by this paper
• Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity

  2014cited by this paper
• Intratumoral Immunization: A New Paradigm for Cancer Therapy

  2014cited by this paper
• The immunocytokine NHS-IL12 as a potential cancer therapeutic

  2014cited by this paper
• Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

  2014cited by this paper
• Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

  2014cited by this paper
• Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

  2014cited by this paper
• Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan

  2013cited by this paper
• Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

  2013cited by this paper
• Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

  2012cited by this paper
• Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting

  2012cited by this paper
• Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cited by this paper
• Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cited by this paper
• Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

  2012cited by this paper
• Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

  2012cited by this paper
• Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface

  2011cited by this paper
• Differential internalization of hu14.18‐IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

  2011cited by this paper
• Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010influential reference
• Anti‐GD2 with an FC point mutation reduces complement fixation and decreases antibody‐induced allodynia

  2010cited by this paper
• Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

  2010cited by this paper
• Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma

  2009cited by this paper
• Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

  2009cited by this paper
• Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

  2009cited by this paper
• CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

  2008cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Combining radiotherapy and immunotherapy: a revived partnership.

  2005cited by this paper
• Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

  2005cited by this paper
• Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

  2004cited by this paper
• Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy

  2004cited by this paper
• Ex Vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer

  2004cited by this paper
• NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy

  2003cited by this paper
• Immune complex-mediated antigen presentation induces tumor immunity.

  2002cited by this paper
• Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation

  1999cited by this paper
• The regulation of CD95 ligand expression and function in CTL.

  1998cited by this paper
• Up‐regulation of Fas (CD95) in human p53wild‐type cancer cells treated with ionizing radiation

  1997cited by this paper
• A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma

  1997cited by this paper
• Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions.

  1997cited by this paper
• Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides

  1997cited by this paper
• Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

  1997cited by this paper
• Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens

  1997cited by this paper
• An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

  1996cited by this paper
• Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

  1996cited by this paper
• Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.

  1996cited by this paper
• gld/gld mice are unable to express a functional ligand for Fas

  1994cited by this paper
• Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody.

  1994cited by this paper
• Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

  1992cited by this paper
• Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma.

  1986cited by this paper

• Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity

  2026cites this paper
• Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

  2026cites this paper
• Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

  2026cites this paper
• Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response

  2026cites this paper
• Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors

  2025cites this paper
• In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma

  2025cites this paper
• Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

  2025cites this paper
• The effects of clinically relevant radionuclides on the activation of a type I interferon response correlate with radionuclide half-life and linear energy transfer and influence radiopharmaceutical antitumor efficacy.

  2025cites this paper
• Facts and hopes in radioimmunotherapy of oligometastatic disease.

  2025cites this paper
• In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma

  2025cites this paper
• Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

  2025influential citation
• Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines.

  2025cites this paper
• Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing

  2025cites this paper
• Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models

  2025cites this paper
• High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?

  2025cites this paper
• Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy

  2024cites this paper
• Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy

  2024cites this paper
• Ranking antibody binding epitopes and proteins across samples from whole proteome tiled linear peptides

  2024cites this paper
• Prodrugs of paclitaxel improve in situ photo‐vaccination

  2024cites this paper
• Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors

  2024cites this paper
• Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade

  2024cites this paper
• Dual and multi-immune activation strategies for emerging cancer immunotherapy

  2024cites this paper
• Bioactive sphingolipids as emerging targets for signal transduction in cancer development.

  2024cites this paper
• S-Sulfenylation Driven Antigen Capture Boosted by Radiation for Enhanced Cancer Immunotherapy.

  2024cites this paper
• A combined radio-immunotherapy regimen eradicates late-stage tumors in mice

  2024cites this paper
• Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation imaging

  2024cites this paper
• The future of cancer treatment: combining radiotherapy with immunotherapy

  2024cites this paper
• Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

  2024cites this paper
• Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

  2024influential citation
• Turning anecdotal irradiation-induced anticancer immune responses into reproducible in situ cancer vaccines via disulfiram/copper-mediated enhanced immunogenic cell death of breast cancer cells

  2024cites this paper
• Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

  2024cites this paper
• Immunological effects of radiopharmaceutical therapy

  2024cites this paper
• Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy

  2024cites this paper
• Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

  2024cites this paper
• In situ vaccination caused by diverse irradiation-driven cell death programs

  2024cites this paper
• Mitochondrial Localized In Situ Self‐Assembly Reprogramming Tumor Immune and Metabolic Microenvironment for Enhanced Cancer Therapy

  2024cites this paper
• Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination

  2023cites this paper
• Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model

  2023influential citation
• NK cells propagate T cell immunity following in situ tumor vaccination.

  2023cites this paper
• Antibody landscape of C57BL/6 mice cured of B78 melanoma via a combined radiation and immunocytokine immunotherapy regimen

  2023cites this paper
• Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation imaging

  2023cites this paper
• ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models

  2023cites this paper
• Multifunctional Au@AgBiS2 Nanoparticles as High‐Efficiency Radiosensitizers to Induce Pyroptosis for Cancer Radioimmunotherapy

  2023cites this paper
• Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model

  2023influential citation
• Turning anecdotal irradiation-induced anti-cancer immune responses into reproducible in situ cancer vaccines via disulfiram/copper-mediated enhanced immunogenic cell death of breast cancer cells

  2023cites this paper
• CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells

  2023cites this paper
• Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an Intracranial Sarcoma Mouse Model

  2023cites this paper
• EISA in Tandem with ICD to Form In Situ Nanofiber Vaccine for Enhanced Tumor Radioimmunotherapy

  2023cites this paper
• Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming

  2023cites this paper
• Hyperbranched Polymer-Based Vaccines for Cancer Immunotherapy.

  2023cites this paper
• Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview.

  2023cites this paper
• Self‐Immolated Nanoadjuvant for In Situ Vaccination Immunotherapy of Colorectal Cancer

  2023cites this paper
• In Situ Vaccination Following Intratumoral Injection of IL2 and Poly-l-lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site

  2023cites this paper
• Biological Insight and Recent Advancement in the Treatment of Neuroblastoma

  2023cites this paper
• Ranking Antibody Binding Epitopes and Proteins Across Samples from Whole Proteome Tiled Linear Peptides

  2023cites this paper
• IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer

  2023cites this paper
• Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist

  2023cites this paper
• Single cell metabolic imaging of tumor and immune cells in vivo in melanoma bearing mice

  2023cites this paper
• Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy

  2023influential citation
• An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.

  2023cites this paper
• Biomaterial-Based In Situ Cancer Vaccines

  2023cites this paper
• Immunotherapy of Neuroblastoma: Facts and Hopes

  2022cites this paper
• Interleukin-12 as an in situ cancer vaccine component: a review

  2022cites this paper
• Short-course neoadjuvant in situ vaccination for murine melanoma

  2022cites this paper
• Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma

  2022cites this paper
• Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy

  2022cites this paper
• Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation

  2022cites this paper
• More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

  2022cites this paper
• Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade

  2022cites this paper
• Image-guided in situ cancer vaccination with combination of multi-functional nano-adjuvant and an irreversible electroporation technique.

  2022cites this paper
• Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

  2022cites this paper
• 45 Prevalent binding motif in C57BL6 mice cured of B78 melanoma via immunotherapy

  2022cites this paper
• On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings

  2022cites this paper
• Epigenetic reprogramming of carrier free photodynamic modulator to activate tumor immunotherapy by EZH2 inhibition.

  2022cites this paper
• Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.

  2022cites this paper
• The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers

  2022cites this paper
• Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

  2022cites this paper
• Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group

  2022cites this paper
• Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy

  2021cites this paper
• Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy

  2021cites this paper
• Cryopreservation from Tumor-Bearing Mice Immune Cells in Samples Requiring Optimizing Flow Cytometric Analysis of

  2021cites this paper
• Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

  2021cites this paper
• Radioimmunotherapy: future prospects from the perspective of brachytherapy

  2021cites this paper
• Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

  2021influential citation
• Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice

  2021cites this paper
• Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

  2021cites this paper
• Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

  2021cites this paper
• Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ

  2021cites this paper
• Using Radiation Therapy to Prime and Propagate an Anti-tumor Immune Response Against Brain Tumors

  2021cites this paper
• Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy

  2021influential citation
• In situ cancer vaccination using lipidoid nanoparticles

  2021cites this paper
• Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes

  2021cites this paper
• Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model

  2021cites this paper
• Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma

  2021cites this paper
• Delivery routes matter: Safety and efficacy of intratumoral immunotherapy.

  2021cites this paper
• Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain

  2021cites this paper
• Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

  2021cites this paper
• Locally Injectable Hydrogels for Tumor Immunotherapy

  2021cites this paper
• A multipurpose brachytherapy catheter to enable intratumoral injection.

  2021cites this paper
• Utilizing Immunocytokines for Cancer Therapy

  2021cites this paper